Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone.

This study has a crossover period, where subjects on standard care alone who do not achieve complete healing within 12 weeks of initiating therapy will be allowed to crossover to receive BR-AC over 12 additional weeks, to evaluate if their wound can achieve complete healing.

Study Overview

• Status: Recruiting
• Conditions: Venous Insufficiency; Venous Leg Ulcer; Venous Stasis; Venous Reflux; Non-infected Venous Leg Ulcer
• Intervention / Treatment: Other: BR-AC; Other: Standard Care

Detailed Description

This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BR-AC plus standard of care versus standard of care only in the treatment of venous leg ulcers. The eligibility criteria for this study will allow for enrollment of subjects with a VLU in the range of 2 cm^2 to 20 cm^2 in area. A lower size of 2 cm^2 was selected to exclude subjects who are likely to heal under compression therapy alone.

During the two-week run-in period, subjects who show a reduction in wound area predictive of achieving complete wound closure within 12 weeks under standardized care alone (i.e., compression therapy) will be excluded from the study. Eliminating these subjects will improve the estimated treatment effect. The criteria for duration, ≥ 4 weeks but ≤ 52 weeks, allows for the selection of those wounds that have demonstrated chronicity but may still have the potential to achieve wound closure.

The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for evaluating venous insufficiency confirmed by duplex Doppler ultrasound examining valvular or venous incompetence, debridement, and compression therapy. Weekly subject visits will help monitor compliance in wound care and compression therapy, as well as to document when wound closureis achieved. The study will implement the use of an electronic imaging and measurement device (eKare inSight®) using a standardized protocol to ensure the measuring of the wound surface area is accurate, highly reproducible, and minimally variable.

There will also be a crossover treatment phase for those patients that were relegated to SOC only. After their 12-week standard of care treatment phase and for only those subjects that did not achieve complete wound closure, will be allowed to crossover for an additional 12 weeks of treatment with the BR-AC product following the protocol and procedures set forth within this document.

A follow-up phase will commence for all subjects that achieve complete wound closure, which is designed to measure longevity and durability of the closed wound. This follow-up period will consist of a four-week follow-up with two visits at each two-week interval.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nick McCoy; Phone Number: 2144571996; Email: nmccoy@biostemtech.com

Study Locations

• United States
  • Alabama
    • Guntersville, Alabama, United States, 35976
      • Recruiting
      • Site 17
  • California
    • Castro Valley, California, United States, 94546
      • Recruiting
      • Site 2b
    • Glendale, California, United States, 91204
      • Recruiting
      • Site 19b
    • Oxnard, California, United States, 93030
      • Recruiting
      • Site 36
    • Oxnard, California, United States, 93036
      • Recruiting
      • Site 37
    • Palmdale, California, United States, 93551
      • Recruiting
      • Site 19
    • San Francisco, California, United States, 94115
      • Recruiting
      • Site 02
    • San Francisco, California, United States, 94117
      • Recruiting
      • Site 2a
    • Sylmar, California, United States, 91342
      • Recruiting
      • Site 04
    • Torrance, California, United States, 90502
      • Recruiting
      • Site 30
    • Vista, California, United States, 92081
      • Recruiting
      • Site 01
  • Florida
    • Aventura, Florida, United States, 33180
      • Recruiting
      • Site 34
    • Coral Gables, Florida, United States, 33134
      • Recruiting
      • Site 27
    • Deerfield Beach, Florida, United States, 33442
      • Recruiting
      • Site 20
    • Fort Walton Beach, Florida, United States, 32547
      • Withdrawn
      • Site 33
    • Miami, Florida, United States, 33126
      • Recruiting
      • Site 35
    • Miami, Florida, United States, 33189
      • Terminated
      • Site 31
  • Illinois
    • O'Fallon, Illinois, United States, 62269
      • Recruiting
      • Site 06
  • Massachusetts
    • Boston, Massachusetts, United States, 02118
      • Recruiting
      • Site 18
  • Missouri
    • St Louis, Missouri, United States, 63128
      • Recruiting
      • Site 32
  • New York
    • Lake Success, New York, United States, 11042
      • Recruiting
      • Site 16
  • Texas
    • Corpus Christi, Texas, United States, 78414
      • Recruiting
      • Site 38
    • Fort Worth, Texas, United States, 76104
      • Recruiting
      • Site 03

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient has signed the informed consent form.
2. Male or female patient at least 18 years of age or older, as of the date of the screening visit.

3. Has a VLU between the knee and ankle (at or above the malleoli), with a surface area in the range of ≥ 2.0 cm2 and ≤ 20.0 cm2 when measured by the investigator staff at the screening visit using the eKare device post debridement.

   1. If the subject presents with > 1, but ≤ 3 VLU on the same leg, the largest ulcer will be selected as the target ulcer.
   2. If the target ulcer is < 1cm from another VLU, the ulcers should be traced as a single target ulcer provided at least one of the ulcers is at least 2.0 cm2 in area and the total surface area of the VLUs is ≤ 20.0 cm2.
4. Target ulcer involves a full-thickness skin loss, but without exposure of tendon, muscle, or bone.
5. Target ulcer duration ≥ 4 weeks but ≤ 52 weeks (12 months).

6. Venous insufficiency confirmed by duplex Doppler ultrasound examining valvular or venous incompetence.

   a. Availability of a complete report of a previous examination performed 12 months of screening will be acceptable, and this examination would not be required to be repeated.

7. Arterial supply adequacy confirmed by any one of the following:

   1. Great toe pressure ≥ 50 mm/Hg
   2. Systolic blood pressure Ankle Brachial Index (ABI) in the range ≥ 0.80 ≤ 1.10
   3. TcPO2 ≥ 40 mmHg from the foot
8. Willing to follow all instructions given by the Investigator, return for all visits, and adhere to compression protocols while on the study.

Exclusion Criteria:

1. A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).
2. Acute Deep Vein Thrombosis (DVT), defined as the first 10 days from onset of symptoms, or any DVT for which compression is considered by the Investigator to be contraindicated.
3. Clinical evidence of ulcer bed infection, or infected hardware.
4. Documented history of osteomyelitis at the target ulcer location within six (6) months preceding the screening visit.
5. Refusal or inability to tolerate compression therapy.
6. Pregnant women.
7. Women of child-bearing potential who are unwilling to avoid pregnancy or use an effective form of birth control.
8. Hemoglobin A1c (HbA1c) level is > 12% (108 mmol/mol).
9. Current therapy with systemic antibiotics.
10. Current therapy with cytotoxic agents.
11. Current therapy with chronic (> 10 days) oral corticosteroids.
12. Current therapy with TNFα inhibitors other than Trental® (pentoxifylline).
13. Has tested positive for Human Immunodeficiency Virus (HIV) or has Acquired Immune Deficiency Syndrome (AIDS).
14. Has malignancy or history of cancer in the preceding 5 years other than non-melanoma skin cancer.
15. Currently on dialysis or planning to start dialysis.
16. Is currently enrolled or participated in another device, drug, or biological trial within 30 days of screening.
17. Therapy of the target ulcer with other birth tissue products, autologous skin graft, Apligraf®, or Dermagraft® within 30 days preceding the screening visit.
18. Therapy of the target ulcer with topical growth factors within thirty (30) days preceding the screening visit.
19. Any previous use of Vendaje®, Vendaje AC®, AmnioWrap2® applied to the target ulcer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BR-AC plus Standard Care; All subjects in the treatment group will receive sponsor-approved standard of care. Standard of care is defined as: Sharp debridement,; Wound cleansing with a neutral, non-irritating and non-toxic solution,; Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and; The UrgoK2™ dual compression system providing around 40 mmHg. Using an appropriate size to cover the entire wound area, BR-AC should be applied directly to the wound surface following sharp debridement. It is recommended that the product be trimmed to fit the area of the wound with sterile scissors before application.	Other: BR-AC; BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method, which, briefly includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C, and electron beam sterilization.
Active Comparator: Standard Care; All subjects in the control group will receive sponsor-approved standard of care. Standard of care is defined as: Sharp debridement,; Wound cleansing with a neutral, non-irritating and non-toxic solution,; Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and; The UrgoK2™ dual compression system providing around 40 mmHg.	Other: Standard Care; Standard Care is defined as: Sharp debridement,; Wound cleansing with a neutral, non-irritating and non-toxic solution,; Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and; The UrgoK2™ dual compression system providing around 40 mmHg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine whether non-ischemic, non-infected VLUs treated with standard care plus BR-AC results in a higher probability of achieving complete wound closure compared to standard care alone.	Percentage of subjects with complete wound closure over the 12-week treatment period, defined as 100% reepithelialization	over the 12-week treatment period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare differences between treatment groups in proportions of wounds with complete wound closure, based on time in days to closure	Percent change from baseline in wound surface area (cm2) at 12-weeks post-randomization	at 12 weeks
To compare differences between treatment groups in percent change in wound area (cm2)	Percent change from baseline in wound surface area (cm2) at 12-weeks post-randomization	at 12 weeks
To determine the total number of applications of BR-AC needed to achieve complete wound closure	Percent change from baseline in wound volume (cm3) at 12-weeks post-randomization	at 12 weeks
To determine whether subjects that crossover and receive standard care plus BR-AC results in a higher probability of achieving complete wound closure over the 12 additional weeks versus standard care alone	Time in days from Visit 18 to initial observation of wound closure (defined as 100% reepithelialization of the wound without drainage) over an additional 12 weeks (Visits 19-30), where healing has been confirmed at two visits two weeks apart	over an additional 12 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects experiencing adverse events, by treatment group	Spontaneously reported and elicited adverse events, coded in MedDRA	over the 17-week study period
Number of participants that acquire clinical signs and symptoms of infections post-randomization	Differences in clinical signs and symptoms of infection from Visit 2 through end of study between the treatment groups	over 12-weeks post-randomization

Collaborators and Investigators

• Sponsor: BioStem Technologies
• Investigators: Study Director: Bert Slade, MD, Independent

Study record dates

Study Major Dates

• Study Start (Actual): February 14, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: January 22, 2025
• First Submitted That Met QC Criteria: February 5, 2025
• First Posted (Actual): February 6, 2025

Study Record Updates

• Last Update Posted (Actual): January 23, 2026
• Last Update Submitted That Met QC Criteria: January 21, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Skin Diseases; Skin Ulcer; Varicose Veins; Leg Ulcer; Skin and Connective Tissue Diseases; Varicose Ulcer; Venous Insufficiency; Health Services Administration; Health Care Quality, Access, and Evaluation; Quality of Health Care; Quality Indicators, Health Care; Standard of Care
• Other Study ID Numbers: BR-AC-VLU-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No